PSX Company Profiles
What listed companies do, how they make money, key financials and Shariah status, researched by the PSX Investors Zone team.
2 companies
Pharmaceuticals
GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited (PSX: GLAXO) is a pharmaceutical company engaged in manufacturing and marketing research-based medicines and other pharmaceutical products in Pakistan. It is part of the global GSK group and operates across therapy areas including anti-infectives, dermatology, analgesics, and vaccines. For the year ended December 31, 2025, the company reported sales of approximately Rs65.90 billion, profit after tax of Rs10.03 billion, and earnings per share of Rs31.48. Its financial performance, product portfolio, manufacturing operations, regulatory environment, and cash-flow position are important factors for fundamental analysis. GLAXO was classified as Shariah-compliant in the PSX KMI All Share screening published in May 2026, based on financial statements available through December 2025. Investors should check subsequent screening updates before making decisions. **Important:** The official PSX company page displays a Risk Warning Alert stating that the company is in continuous violation of specified exchange clauses and carries a risk of trading suspension or delisting. Investors should review the latest PSX disclosures and understand this regulatory risk before evaluating the stock. Sources: [PSX company profile and financials](https://dps.psx.com.pk/company/GLAXO) | [GSK Pakistan](https://pk.gsk.com/en-pk/company/) | [PSX KMI screening notice](https://www.psx.com.pk/psx/files/?file=277899-1.pdf)
Pharmaceuticals
Haleon Pakistan Limited
Haleon Pakistan Limited (PSX: HALEON) is a listed consumer healthcare company manufacturing, marketing and selling over-the-counter health products in Pakistan. Formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited, it became part of the independent Haleon group following the consumer healthcare demerger. Its product portfolio includes well-known brands in pain relief, oral health, respiratory health and vitamins and supplements. For 2025, the company reported revenue of Rs43.106 billion, profit after tax of Rs6.373 billion and EPS of Rs54.45. Its latest reviewed 2026 quarterly results, for the quarter ended June 30, reported revenue of Rs10.072 billion and profit after tax of Rs1.676 billion. Haleon Pakistan was classified as Shariah-compliant in the PSX-KMI All Share Islamic Index recomposition published in May 2026, based on December 2025 financial statements. However, the official PSX profile displays a Risk Warning Alert concerning continuous exchange-rule violations and potential trading suspension or delisting. Investors should verify the latest exchange notices and Shariah screening before making decisions.